Novonesis Beheer

Hoe is Ester Baiget's beloning veranderd ten opzichte van Novonesis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	€283m
Mar 31 2024	n/a	n/a	€332m
Dec 31 2023	€4m	€1m	€406m
Sep 30 2023	n/a	n/a	€430m
Jun 30 2023	n/a	n/a	€460m
Mar 31 2023	n/a	n/a	€487m
Dec 31 2022	€3m	€1m	€494m
Sep 30 2022	n/a	n/a	€460m
Jun 30 2022	n/a	n/a	€418m
Mar 31 2022	n/a	n/a	€416m
Dec 31 2021	€3m	€1m	€423m
Sep 30 2021	n/a	n/a	€427m
Jun 30 2021	n/a	n/a	€409m
Mar 31 2021	n/a	n/a	€389m
Dec 31 2020	€3m	€927k	€380m

Compensatie versus markt: De totale vergoeding ($USD 4.13M ) Ester } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Danish markt ($USD 3.66M ).

Compensatie versus inkomsten: De beloning van Ester is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Ester Baiget (53 yo)

4.8yrs

Tenure

€3,903,958

Compensatie

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ester Baiget	President & CEO	4.8yrs	€3.90m	geen gegevens
Rainer Lehmann	Executive VP & CFO	less than a year	€858.60k	geen gegevens
Anders Lund	Chief Operating Officer	less than a year	€1.03m	geen gegevens
Claus Fuglsang	Chief Scientific Officer	4.2yrs	geen gegevens	geen gegevens
Tobias Bjorklund	Head of Investor Relations	no data	geen gegevens	geen gegevens
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	geen gegevens	geen gegevens
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3.6yrs	geen gegevens	geen gegevens
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.8yrs	€1.02m	geen gegevens
Amy Byrick	Executive Vice President of Human Health Biosolutions	3.6yrs	geen gegevens	geen gegevens
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	geen gegevens	geen gegevens
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	geen gegevens	geen gegevens
Peter Rosholm	Chief Executive Officer of Albumedix	8.8yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NSIS B wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jesper Brandgaard	Vice Chair of the Board	less than a year	geen gegevens	geen gegevens
Cornelis de Jong	Independent Chairman	4.8yrs	€239.07k	0.0011% DKK 2.1m
Kim Stratton	Independent Director	7.8yrs	€173.33k	geen gegevens
Kasim Kutay	Director	7.8yrs	€107.73k	0.00023% DKK 442.8k
Heine Dalsgaard	Director	4.8yrs	€143.55k	0.00065% DKK 1.3m
Lise Kaae	Director	less than a year	geen gegevens	geen gegevens
Lena Holskov	Employee Representative Director	11.8yrs	€66.91k	geen gegevens
Anders Knudsen	Employee Representative Director	11.8yrs	€71.77k	geen gegevens
Sharon James	Independent Director	4.8yrs	€143.55k	geen gegevens
Preben Nielsen	Employee Representative Director	3.7yrs	€107.73k	0.000090% DKK 173.3k
Jens Obro	Employee Representative Director	3.7yrs	€71.77k	0.00012% DKK 231.0k
Morten Otto Sommer	Independent Director	2.7yrs	€137.51k	0.00022% DKK 423.6k

4.8yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NSIS B wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Novonesis Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Novonesis A/S Announces Board Changes

Novozymes A/S Announces Board Appointments

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Recent updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022